Can two common compounds supercharge CAR-T against myeloma?
NCT ID NCT06940297
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This phase II trial at Mayo Clinic is testing whether adding dasatinib and quercetin to standard CAR-T therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. The study will enroll 44 adults who have already tried at least three other therapies. Participants receive the drug combination along with chemotherapy and CAR-T cells, and researchers will measure how many achieve undetectable cancer levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dasatinib and quercetin
- What this could lead to
- If successful, this combination could improve the effectiveness of CAR-T therapy for multiple myeloma, helping more patients achieve deep remission.
- What could go wrong
- This is a small, early-phase trial with only 44 participants. The added benefit of dasatinib and quercetin is unproven, and side effects from the combination are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?